Chang Full-Young
Full-Young Chang, Environmental Health and Safety Office and Division of Gastroenterology, Taipei Veterans General Hospital, and National Yang-Ming University School of Medicine, Taipei 11217, Taiwan.
World J Gastroenterol. 2014 Mar 14;20(10):2499-514. doi: 10.3748/wjg.v20.i10.2499.
Irritable bowel syndrome (IBS) is common in the society. Among the putative pathogeneses, gut dysmotility results in pain and disturbed defecation. The latter is probably caused by the effect of abnormal gut water secretion. The interaction between abnormal gas accumulation, abdominal pain and bloating remains controversial. Visceral hypersensitivity and its modification along with the central transmission are the characteristics of IBS patients. The identification of biologic markers based on genetic polymorphisms is undetermined. Imbalanced gut microbiota may alter epithelial permeability to activate nociceptive sensory pathways which in turn lead to IBS. Certain food constituents may exacerbate bowel symptoms. The impact of adult and childhood abuses on IBS is underestimated. Using the concept of biopsychosocial dysfunction can integrate multidimensional pathogeneses. Antispasmodics plus stool consistency modifiers to treat the major symptoms and defecation are the first-line drug treatment. New drugs targeting receptors governing bowel motility, sensation and secretion can be considered, but clinicians must be aware of their potential serious side effects. Psychiatric drugs and modalities may be the final options for treating intractable subjects. Probiotics of multi-species preparations are safe and worth to be considered for the treatment. Antibiotics are promising but their long-term safety and effectiveness are unknown. Diet therapy including exclusion of certain food constituents is an economic measure. Using relatively safe complementary and alternative medicines (CAMs) may be optional to those patients who failed classical treatment. In conclusion, IBS is a heterogeneous disorder with multidimensional pathogeneses. Personalized medicines with multidisciplinary approaches using different classes of drugs, psychiatric measures, probiotics and antibiotics, dietary therapy, and finally CAMs, can be considered.
肠易激综合征(IBS)在社会中很常见。在假定的发病机制中,肠道动力障碍会导致疼痛和排便紊乱。后者可能是由异常的肠道水分泌作用引起的。异常气体积聚、腹痛和腹胀之间的相互作用仍存在争议。内脏高敏感性及其改变以及中枢传导是IBS患者的特征。基于基因多态性的生物标志物的鉴定尚未确定。肠道微生物群失衡可能会改变上皮通透性,从而激活伤害性感觉通路,进而导致IBS。某些食物成分可能会加重肠道症状。成人和儿童期受虐对IBS的影响被低估了。运用生物心理社会功能障碍的概念可以整合多维度的发病机制。使用解痉药加粪便稠度调节剂来治疗主要症状和排便问题是一线药物治疗方法。可以考虑针对控制肠道动力、感觉和分泌的受体的新药,但临床医生必须意识到其潜在的严重副作用。精神科药物和治疗方式可能是治疗难治性患者的最终选择。多种益生菌制剂安全,值得考虑用于治疗。抗生素前景广阔,但其长期安全性和有效性尚不清楚。包括排除某些食物成分的饮食疗法是一种经济的措施。对于那些经典治疗失败的患者,使用相对安全的补充和替代医学(CAMs)可能是一种选择。总之,IBS是一种具有多维度发病机制的异质性疾病。可以考虑采用多学科方法的个性化药物治疗,使用不同种类的药物、精神科措施、益生菌和抗生素、饮食疗法,最后是CAMs。